SCHEMBL13623452

SCHEMBL13623452

O=C(O)N1CCc2ccc(Cl)cc2C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.50
ESR2 Q92731 3/20 0.50
TAS1R3 Q7RTX0 1/20 0.50
TAS1R1 Q7RTX1 1/20 0.50
TAS1R2 Q8TE23 1/20 0.50
AKR1C3 P42330 2/20 0.49
ERCC1 P07992 1/20 0.49
ERCC4 Q92889 1/20 0.49
NPC1 O15118 1/20 0.48
CASP3 P42574 1/20 0.48
RAB9A P51151 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
GAA P10253 2/20 0.48
RXFP1 Q9HBX9 1/20 0.47
NOTUM Q6P988 2/20 0.46
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29390456 1.00 ESR1 (0.50) ESR1ESR2TAS1R3TAS1R1TAS1R2
SCHEMBL13892490 0.86 DPP4 (0.47) ESR1ESR2TAS1R3TAS1R1TAS1R2
SCHEMBL8221038 0.85 NOTUM (0.63) ESR1ESR2TAS1R3TAS1R1TAS1R2
SCHEMBL1648634 0.85 ESR2 (0.68) ESR1ESR2KMT2AMEN1NOTUM
SCHEMBL30199245 0.85 ESR2 (0.68) ESR1ESR2KMT2AMEN1NOTUM
SCHEMBL29097879 0.84 KMT2A (0.44) ESR1ESR2TAS1R3TAS1R1TAS1R2
SCHEMBL10802449 0.83 HDAC8 (0.50) ESR1ESR2TAS1R3TAS1R1TAS1R2
SCHEMBL7697763 0.81 CCNK (0.53) ESR1ESR2TAS1R3TAS1R1TAS1R2
SCHEMBL2821470 0.81 ESR1 (0.76) ESR1ESR2TAS1R3TAS1R1TAS1R2
SCHEMBL29989790 0.81 ESR1 (0.76) ESR1ESR2TAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286843-A1 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION HOFFMANN-LA ROCHE INC. 2009-11-19 US disclosed
US-20090111982-A1 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION HOFFMANN-LA ROCHE INC. 2009-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111982-A1 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, ZC3HAV1 ESR1 3277/4885ESR2 2681/4885TAS1R3 3969/4885
US-20090286843-A1 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, ZC3HAV1 ESR1 3277/4885ESR2 2681/4885TAS1R3 3969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.